Association annual meeting assembles over 19,000 discovery scientists and Clinical researchers from around the world to share the latest advances to solving cancers
LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing and solutions for cell therapy, will be attending the AACR annual meeting at the Walter E. Washington Convention Center in Washington, D.C. to showcase its latest primary blood products used in support of cancer research. The meeting is host to over 19,000 scientists and other cancer professionals and patient advocacy groups that focus on translating the mechanisms of cancer pathologies into safe and effective treatments to improve patient’s lives. HemaCare will be exhibiting to increase awareness of its expanded offering of human primary blood cells from different disease states.
“We are attending AACR to help researchers and developers of cutting-edge cell therapies understand how our cells and capabilities can support their research and aid in their progress toward finding cures for cancer.”
“The need for highly pure, viable, and functional hematopoietic stem cells and primary cells is critical in the development of effective cancer treatments,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We are attending AACR to help researchers and developers of cutting-edge cell therapies understand how our cells and capabilities can support their research and aid in their progress toward finding cures for cancer.”
Visit HemaCare and meet several members of our sales, marketing, and executive team in Washington D.C. at AACR at Booth #952 or view our product story at www.hemacare.com.
About HemaCare
HemaCare specializes in the customization of human-derived biological products and services for customer’s research and cell therapy protocols. HemaCare’s network of FDA-registered, GMP/GTP-compliant collection centers ensures donor material is available for fresh shipment to customers, as well as for internal use within HemaCare’s isolation laboratory. In this laboratory, human biological material such as peripheral blood, bone marrow, and cord blood from donor and patient subjects is isolated into various primary cell types for distribution to customers in fresh and frozen formats. HemaCare’s extensive registry of well-characterized repeat donors provides consistent primary human cells and biological products for advanced biomedical research and cellular therapy process development.
For 39 years, HemaCare has provided human-derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provided a wide range of consulting services. HemaCare directly supports benchtop immunology and oncology research, compound screening for drug discovery, and assay development and qualification, as well as enables customers to advance both autologous and allogeneic cellular therapies. For more information, please visit www.hemacare.com.
HemaCare Corporation
Rochelle Martel, 818-728-8868
rmartel@hemacare.com
